Editco Bio Inc.

Editco Bio Inc. is a self-certified small disadvantaged business headquartered in Redwood City, California, that specializes in advanced biomedical research services with a focus on cell line generation and genetic modification. Registered with SAM.gov in July 2024, the company provides specialized biological research materials and services to federal scientific agencies, positioning itself as a reliable vendor for complex cellular engineering projects that support translational science and drug discovery initiatives.

Editco Bio Inc. has secured four federal contract awards totaling $85,457, all issued as firm fixed-price purchase orders without set-aside designations. The National Center for Advancing Translational Sciences (NCATS), a component of the National Institutes of Health, has been the company's primary funding partner, awarding three contracts valued at $74,007. These NCATS contracts, awarded between September 2024 and September 2025, encompassed the delivery of specialized engineered cell lines including HIBIT-tagged FLT3 cell lines ($14,857), SFRP1-HIBIT-tagged cell lines for small molecule screening ($24,150), and a Synthego product ($35,000). Additionally, the National Heart Lung and Blood Institute awarded a $11,450 purchase order in August 2024 for knock-in cell line generation services to support Dr. Martina's cell biology experiments. Collectively, these contracts demonstrate Editco Bio Inc.'s expertise in providing precisely engineered cell models with specialized tagging and genetic modifications, designed to support downstream pharmaceutical screening, biomedical research, and translational science applications across multiple federal research institutes.